Back to search

Article

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

2023-07-18

Abstract excerpt

This phase Ib study was performed to determine the safety, the maximal tolerated dose (MTD), and recommended phase II dose (RP2D) of capecitabine with alpleisib in patients with advanced solid tumors. Regardless of PIK3CA mutation, patients were administered orally once daily alpelisib (200mg and 300mg) and twice daily capecitabine (850mg/m 2 , 1,000mg/m 2 , 1,250mg/m 2 , days 1–14) every 3 weeks. Standard “3+3” d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d974fd70-e7b8-559c-973c-f2eab4a476c0
DOI
10.21203/rs.3.rs-3174557/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumorsDOI 10.21203/rs.3.rs-3174557/v1
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.Semantic proximity
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.Semantic proximity
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Semantic proximity
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.Semantic proximity
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Semantic proximity
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.Semantic proximity
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Semantic proximity
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.Semantic proximity
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting.Semantic proximity
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.Semantic proximity
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.Semantic proximity
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.Semantic proximity
Select a neighboring publication to make it the new centre.